MARKET

ENGNW

ENGNW

Forbion European Acquisition Corp
NASDAQ
2.530
0.00
0.00%
Opening 09:30 04/01 EDT
OPEN
--
PREV CLOSE
2.530
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.5100
MARKET CAP
--
P/E (TTM)
-1.1230
1D
5D
1M
3M
1Y
5Y
1D
ENGENE HOLDINGS INC. <ENGN.O>: OPPENHEIMER CUTS TARGET PRICE TO $30 FROM $33
Reuters · 03/11 13:57
ENGENE HOLDINGS INC - SALES AGREEMENT ALLOWS OFFERING OF COMMON SHARES UP TO $100 MLN - SEC FILING
Reuters · 03/09 11:16
enGene Q1 net loss attributable to common shareholders rises 21% to USD 29.75 million on 17% higher operating expenses of USD 31.19 million
Reuters · 03/09 11:01
ENGENE HOLDINGS Q1 NET LOSS $0.44 PER SHARE
Reuters · 03/09 11:00
ENGENE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 03/09 11:00
enGene to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Reuters · 02/20 13:00
ENGENE HOLDINGS INC - FILES FOR MIXED SHELF OF UPTO $400 MLN - SEC FILING - SEC FILING
Reuters · 02/19 21:28
enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 02/04 13:01
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.